Defence Therapeutics Inc.
DTC.CNCNQHealthcare● Active
$0.50
$-0.01(-1.96%)
Market Cap$28684985
P/E Ratio—
52W High$0.93
52W Low$0.435
Defence Therapeutics Inc. (DTC.CN) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · DTC.CN · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-06 | 2024-06 | 2023-06 | 2022-06 | 2021-06 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | ($0.00B) | ($0.00B) | ($0.00B) | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.00B | $0.01B | $0.01B | $0.00B | $0.00B |
| Operating Income | ($0.00B) | ($0.01B) | ($0.01B) | ($0.00B) | ($0.00B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.00B) | ($0.01B) | ($0.01B) | ($0.01B) | ($0.00B) |
| Income Tax Expense | $0.00B | $0.00B | ($0.00B) | $0.00B | $0.00B |
| Net Income | ($0.00B) | ($0.01B) | ($0.01B) | ($0.01B) | ($0.00B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.07 | $-0.30 | $-0.17 | $-0.20 | $-0.11 |
| Wtd Avg Shares | 0.05B | 0.04B | 0.04B | 0.04B | 0.03B |
| EBITDA | ($0.00B) | ($0.01B) | ($0.01B) | $0.00B | $0.00B |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · CAD · B
Explore more Defence Therapeutics Inc. data
About Defence Therapeutics Inc. (DTC.CN) Income Statement
Defence Therapeutics Inc. (DTC.CN) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, DTC.CN reported revenue of $0.00B, gross profit of ($0.00B) (gross margin —), and net income of ($0.00B) — a net profit margin of —.
Frequently asked questions
DTC.CN · 4 questionsDefence Therapeutics Inc. (DTC.CN) reported revenue of $0.00B for 2025, down —% year-over-year.
DTC.CN revenueDTC.CN salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09